Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Jan

Sungen BioMed Unveils Next-Generation “SG Linker-Payload” Platform for ADC Development at 2026 J.P. Morgan Healthcare Conference

Following the successive announcements of significant progress in its first-in-class antibody drug SGC001 for acute myocardial infarction and next-generation immuno-oncology pipeline SGT003, Sungen Bi...

Read article >

Jan

2026 China FIC Innovation and Collaboration Summit Held in San Francisco, Chinese Pharmaceutical Companies Showcase Innovative Achievements

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ --During the 2026 J.P. Morgan Healthcare Conference (JPM), the 2026 China FIC Innovation & Collaboration Summit was successfully held in San Francisco, th...

Read article >

Jan

CHINADAILY | US-China biotech summit builds bridges for innovative drug partners

The 2026 China FIC Innovation and Collaboration Summit is held on Sunday in San Francisco. The summit, hosted by the Zhongguancun First-in-Class Innovative Drug Global Strategic Development Alliance, ...

Read article >